|18th February 2021||Thomas John Dietz||9,000||Grant/award etc.||$0.00|
|10th February 2021||Amit Sachdev||2,421||Payment by withholding||$214.16||$518,481.36|
|3rd February 2021||Amit Sachdev||10,324||Grant/award etc.||$0.00|
|3rd February 2021||Amit Sachdev||10,126||Grant/award etc.||$0.00|
|3rd February 2021||Amit Sachdev||11,627||Grant/award etc.||$0.00|
|8th January 2021||Eldon C. Iii Mayer||1,690||Open or private sale||$11.68||$19,739.20|
|8th December 2020||Amit Sachdev||3,391||Bona fide gift||$0.00|
|13th November 2020||Evan Loh||20,928||Open or private sale||$5.93||$124,103.04|
|12th November 2020||Evan Loh||75,000||Grant/award etc.||$0.00|
|29th October 2020||Evan Loh||39,479||Exercise of derivative||$4.30||$169,759.70|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases.